PubMed

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS.

Diabetes Care. 2004 Nov;27(11):2654-60.PMID: 15505001 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.

Nishio K, Shigemitsu M, Kodama Y, Konno N, Katagiri T, Kobayashi Y.

Cardiovasc Revasc Med. 2009 Jan-Mar;10(1):5-11.PMID: 19159848 [PubMed - indexed for MEDLINE]Related articles

A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T.

Diabetes Care. 2006 Jan;29(1):101-6.PMID: 16373904 [PubMed - indexed for MEDLINE]Related articlesFree article

Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.

Fang CC, Ng Jao YT, Yi-Chen, Yu CL, Chen CL, Wang SP.

Angiology. 2007 Oct-Nov;58(5):523-34.PMID: 18024934 [PubMed - indexed for MEDLINE]Related articles

Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.

Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF.

Am Heart J. 2004 May;147(5):e23.PMID: 15131558 [PubMed - indexed for MEDLINE]Related articles

Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.

Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolín R, Goicolea J, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Avilés F, Macaya C; DIABETES Investigators.

Circulation. 2005 Oct 4;112(14):2175-83.PMID: 16203930 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.

Finn AV, Oh JS, Hendricks M, Daher M, Cagliero E, Byrne RM, Nadelson J, Crimins J, Kastrati A, Schömig A, Bruskina O, Palacios I, John MC, Gold HK.

Am Heart J. 2009 Feb;157(2):383.e1-8.PMID: 19185649 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study.

Takagi T, Yamamuro A, Tamita K, Katayama M, Morioka S.

J Cardiol. 2005 Apr;45(4):139-47.PMID: 15875535 [PubMed - indexed for MEDLINE]Related articles

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K.

J Am Coll Cardiol. 2000 Nov 1;36(5):1529-35.PMID: 11079654 [PubMed - indexed for MEDLINE]Related articles

[Efficacy of sirolimus-eluting stent implantation in diabetic patients with very small vessels (< or = 2.25 mm). Insights from the DIABETES trial]

Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, Gómez-Hospital JA, Sanmartín M, Bañuelos C, Moreno R, Escaned J, Fernández C, Costa MA, Fernández-Avilés F, Macaya C.

Rev Esp Cardiol. 2006 Oct;59(10):1000-7. Spanish. PMID: 17125709 [PubMed - indexed for MEDLINE]Related articlesFree article

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).

Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J; POPPS Investigators.

JACC Cardiovasc Interv. 2009 Jun;2(6):524-31.PMID: 19539256 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome.

Cao Z, Zhou YJ, Zhao YX, Liu YY, Guo YH, Cheng WJ.

Chin Med J (Engl). 2006 Jul 20;119(14):1171-5.PMID: 16863608 [PubMed - indexed for MEDLINE]Related articlesFree article

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.

Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M.

Circulation. 2005 Nov 1;112(18):2792-8. Epub 2005 Oct 24.PMID: 16246947 [PubMed - indexed for MEDLINE]Related articlesFree article

Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results.

Rodriguez AE, Rodriguez Alemparte M, Fernandez Pereira C, Vigo CF, Sampaolesi A, Bernardi V, Marchand E, Tronge J, Palacios IF; LASMAL II Investigators.

Am Heart J. 2005 Jul;150(1):188.PMID: 16086559 [PubMed - indexed for MEDLINE]Related articles

Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials.

Rosmarakis ES, Falagas ME.

Am Heart J. 2007 Jul;154(1):144-50. Review.PMID: 17584567 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.

Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J.

Am Heart J. 2003 Aug;146(2):E5.PMID: 12891212 [PubMed - indexed for MEDLINE]Related articles

Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.

Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Staico R, Feres F, Centemero M, Tanajura LF, Abizaid A, Pinto I, Maldonado G, Seixas A, Costa MA, Paes A, Mintz GS, Sousa JE.

Circulation. 2004 Feb 24;109(7):861-6. Epub 2004 Feb 2.PMID: 14757690 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.

Metabolism. 2007 Oct;56(10):1396-401.PMID: 17884451 [PubMed - indexed for MEDLINE]Related articles

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.

Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators.

Minerva Cardioangiol. 2007 Feb;55(1):1-18. English, Italian. PMID: 17287679 [PubMed - indexed for MEDLINE]Related articles

A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.

Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, Lee MK, Li SK, Ng W, Lee PY, Lam KF, Tse HF, Lau CP.

J Invasive Cardiol. 2005 Oct;17(10):534-8.PMID: 16204748 [PubMed - indexed for MEDLINE]Related articles